Bosutinib (SKI-606) Licensed by Pfizer

Catalog No.S1014

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7NEC3enZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3KwUGlEPTB;MD6wPFI{OSBizszNM17RTnNCVkeHUh?=
SW756NXzLXmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nLRmlEPTB;MD6xOFAzPCBizszNM2PNPHNCVkeHUh?=
CTV-1M{f1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo[xTWM2OD1yLkG2N|k5KCEQvF2=MXHTRW5ITVJ?
HSC-4NHPvOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfnZVAzUUN3ME2wMlE4OTV6IDFOwG0>MWTTRW5ITVJ?
LAMA-84M1K0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rhZ2lEPTB;MD6yPFY3PCBizszNM1\rW3NCVkeHUh?=
KU812MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVH6U3NPUUN3ME2wMlM1ODZ6IDFOwG0>NFX0bnlUSU6JRWK=
HCC1806MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGX1b|RKSzVyPUCuN|UzOTZiIN88US=>MXLTRW5ITVJ?
DOKMnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{T5ZWlEPTB;MD6zO|c5PiBizszNMWDTRW5ITVJ?
NCI-H209NYLiZ5NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzaSW0yUUN3ME2wMlQxQDB6IDFOwG0>M4C1[XNCVkeHUh?=
EoL-1-cellNV62RXV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1WyfGlEPTB;MD60NVU4PiBizszNNVnCNmY{W0GQR1XS
H9NIT1V3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITYSVNKSzVyPUCuOFM1PjRiIN88US=>NXO5clRrW0GQR1XS
EM-2MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHxTWM2OD1yLkSzPFkhKM7:TR?=NIPLSmdUSU6JRWK=
NCI-H292Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPGWpdDUUN3ME2wMlQ1OTB6IDFOwG0>MYrTRW5ITVJ?
697NVjsRY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjrZpdKSzVyPUCuOFU3OzNiIN88US=>MVLTRW5ITVJ?
BHT-101M{jLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XJZ2lEPTB;MD60OlU6KCEQvF2=NH3GbGJUSU6JRWK=
BE-13NG\Hc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnLdXRKSzVyPUCuOFg2PzJiIN88US=>MYrTRW5ITVJ?
RS4-11NUfxW21DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTBwNEi1PFQhKM7:TR?=MkHuV2FPT0WU
IGROV-1NXXNdmpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\rTWM2OD1yLkS4O|k4KCEQvF2=NWLZWGJuW0GQR1XS
KE-37MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwNEm1NFkhKM7:TR?=NF\0cVJUSU6JRWK=
BV-173NYXQZZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwNUC3PVIhKM7:TR?=NFX5TXlUSU6JRWK=
MEG-01NVy4fmVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXpbY9LUUN3ME2wMlUyOjF2IDFOwG0>NIHrTYRUSU6JRWK=
LB2241-RCCMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHzTWM2OD1yLkWzO|E5KCEQvF2=MV7TRW5ITVJ?
ACHNM176TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HWTGlEPTB;MD61OFA3QSBizszNMYnTRW5ITVJ?
CTB-1MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHVfIRNUUN3ME2wMlU1QDJiIN88US=>NXmwVIlHW0GQR1XS
HT-1080NXTCd2p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTBwNUWzOFkhKM7:TR?=MYrTRW5ITVJ?
CHL-1MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Wzd2lEPTB;MD61OVQ3PSBizszNM2HSe3NCVkeHUh?=
EW-3NWTzU25wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\DUYpHUUN3ME2wMlU2QTN3IDFOwG0>MkPzV2FPT0WU
ES1NX3vTXczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvPZVc4UUN3ME2wMlY4PDl6IDFOwG0>MkfUV2FPT0WU
KASUMI-1NGXvVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnZcotKSzVyPUCuO|I{OyBizszNNF;D[opUSU6JRWK=
SW13NYXKN2M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrGTWM2OD1yLkezO|k5KCEQvF2=MYDTRW5ITVJ?
A3-KAWNVXoc211T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml:4TWM2OD1yLke5NlA5KCEQvF2=MknqV2FPT0WU
LB771-HNCMmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTBwOEOxNFQhKM7:TR?=NXLKcZBLW0GQR1XS
OC-314M1Tue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDEVY9KSzVyPUCuPFY6PjViIN88US=>M2LieHNCVkeHUh?=
MLMAMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlKzTWM2OD1yLkmwOlc2KCEQvF2=NVGySWw1W0GQR1XS
KARPAS-45MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml73TWM2OD1yLkmyOFY3KCEQvF2=NXL1Z3h5W0GQR1XS
CAL-27M{fkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTBwOUK5NFYhKM7:TR?=NYfFXIl4W0GQR1XS
SK-NEP-1Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTBwOUeyOFghKM7:TR?=NVLmeXIxW0GQR1XS
COR-L105MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnuxTWM2OD1zLkCwN|k1KCEQvF2=NVTxUHNmW0GQR1XS
TI-73MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3RcGQzUUN3ME2xMlAyPjViIN88US=>Mly1V2FPT0WU
JVM-3NHThcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXzPZRKSzVyPUGuNFUxOTdiIN88US=>NX;kZWVnW0GQR1XS
HAL-01NVHPV2UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnrcoVKSzVyPUGuNFg5OSBizszNNXTZendNW0GQR1XS
QIMR-WILNX\SdVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jLbmlEPTB;MT6wPVA2QCBizszNMUPTRW5ITVJ?
HSC-3Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUi0OGFEUUN3ME2xMlEyPzh|IDFOwG0>MUjTRW5ITVJ?
KY821Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3aTWM2OD1zLkGzN|UyKCEQvF2=NHjRRodUSU6JRWK=
5637NWr2[nNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml72TWM2OD1zLkGzPFA{KCEQvF2=NXTaTnB2W0GQR1XS
CAL-33MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnKTWM2OD1zLkG5N|AzKCEQvF2=MYLTRW5ITVJ?
ES4NYmyVYppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLFW3U5UUN3ME2xMlIxPzliIN88US=>NFnXWGpUSU6JRWK=
BHYMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3RdYtuUUN3ME2xMlIzQDl{IDFOwG0>NWTQcIpVW0GQR1XS
LB1047-RCCNGG2UoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTFwMkO3PFUhKM7:TR?=NWf6R2tlW0GQR1XS
H4MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\4SHU6UUN3ME2xMlI1OjV3IDFOwG0>NUjEd4pNW0GQR1XS
RPMI-8866MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XBbmlEPTB;MT6yOlExPiBizszNMYDTRW5ITVJ?
HO-1-N-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFwMk[zOlkhKM7:TR?=Mk\BV2FPT0WU
BB30-HNCMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4m3dmlEPTB;MT6yPFcyPCBizszNMXTTRW5ITVJ?
PC-14NWTBVXN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rhemlEPTB;MT6yPVIxPSBizszNMVzTRW5ITVJ?
NUGC-3MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2O5b2lEPTB;MT6yPVM2PiBizszNMmDuV2FPT0WU
A4-FukNXTnSnBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zpZmlEPTB;MT6zNFcxPCBizszNMl7DV2FPT0WU
MHH-NB-11MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2e2R2lEPTB;MT6zNVM5OyBizszNNX\pOlJMW0GQR1XS
KOSC-2MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPyZ3lKSzVyPUGuN|E4PzViIN88US=>NH\TW2pUSU6JRWK=
A498NIHsSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoP1TWM2OD1zLkSwNVE{KCEQvF2=NYTJbFNkW0GQR1XS
KG-1MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\BZmlEPTB;MT60NVI4OyBizszNMW\TRW5ITVJ?
DELMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLhRohKSzVyPUGuOFM3PTdiIN88US=>MVHTRW5ITVJ?
EW-16NVzxWmFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorOTWM2OD1zLkSzPVc{KCEQvF2=NXjWXJpXW0GQR1XS
BPH-1Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTFwNES4NFUhKM7:TR?=MXLTRW5ITVJ?
JARMlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUO1TmxsUUN3ME2xMlQ6OzZiIN88US=>NWS2NmtqW0GQR1XS
J-RT3-T3-5M17XXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{faemlEPTB;MT61NVczOiBizszNMn[yV2FPT0WU
A375M1jtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvzTWM2OD1zLkWxO|czKCEQvF2=MV\TRW5ITVJ?
SW954MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXOTWM2OD1zLkW1NFA4KCEQvF2=MUHTRW5ITVJ?
Ca9-22M{LZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPmTWM2OD1zLkW2NlYhKM7:TR?=MUTTRW5ITVJ?
D-566MGM1zjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTFwNUexOVUhKM7:TR?=NVjscXJOW0GQR1XS
SCC-15NW\sSohZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDEdWo3UUN3ME2xMlYyQDB2IDFOwG0>NVToc5luW0GQR1XS
HD-MY-ZM4XabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnkXVRnUUN3ME2xMlY{PTh2IDFOwG0>M4nye3NCVkeHUh?=
HT-1376MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1WwUGlEPTB;MT62OFM3KCEQvF2=MXnTRW5ITVJ?
CAL-54M32w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLkUm5KSzVyPUGuOlU4ODliIN88US=>NW[xenp4W0GQR1XS
ONS-76MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVi2R4d{UUN3ME2xMlY4PTVzIDFOwG0>NX64NYt[W0GQR1XS
EFO-27Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TDU2lEPTB;MT62PFkzKCEQvF2=MWDTRW5ITVJ?
769-PMnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXGzdmdGUUN3ME2xMlY6PTl4IDFOwG0>M37CdHNCVkeHUh?=
MV-4-11MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXQNlRKSzVyPUGuOlk5PTZiIN88US=>MXPTRW5ITVJ?
NKM-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\FS4N4UUN3ME2xMlcyQDB{IDFOwG0>M2HDfHNCVkeHUh?=
LOXIMVINED6bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIroclNKSzVyPUGuO|Q2QTliIN88US=>M2rhc3NCVkeHUh?=
KYSE-140MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTPXnhKSzVyPUGuO|U3PTViIN88US=>M4rIV3NCVkeHUh?=
ES5NIGyOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHvb5dKSzVyPUGuPFY4PDdiIN88US=>M1r4VnNCVkeHUh?=
BB65-RCCNHe3S5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHpZ|hKSzVyPUGuPFk5PDliIN88US=>NEXrSodUSU6JRWK=
HNM3nEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jpbmlEPTB;MT64PVg4PCBizszNM3XEOnNCVkeHUh?=
A101DNUHj[GF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjlN5pbUUN3ME2xMlk{PjJ6IDFOwG0>M2W3R3NCVkeHUh?=
LoVoNX7vcoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\TTWM2OD1zLkm3Olc6KCEQvF2=MonjV2FPT0WU
NCI-H526MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{OxVmlEPTB;MT65PVMzPSBizszNNYLtOFNOW0GQR1XS
NCI-H1693NXz3VnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkT2TWM2OD1zLkm5PFg5KCEQvF2=MVjTRW5ITVJ?
OVCAR-4Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTJwMEC0N|UhKM7:TR?=MlPmV2FPT0WU
SK-HEP-1NEXRU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPTRYNxUUN3ME2yMlAxPzR3IDFOwG0>MWLTRW5ITVJ?
C2BBe1NGDnSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;vTWM2OD1{LkCzN|czKCEQvF2=MmLrV2FPT0WU
MEL-JUSONH3YTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJwMES0OlQhKM7:TR?=NI\GSllUSU6JRWK=
MOLT-16NXrz[Wk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnMTWM2OD1{LkC3NFU5KCEQvF2=Ml62V2FPT0WU
NBsusSRNHvSOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\BV4ZUUUN3ME2yMlA6QDh7IDFOwG0>NF7rSFBUSU6JRWK=
TK10NHnEV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3yTWM2OD1{LkGzOFU5KCEQvF2=M1LSc3NCVkeHUh?=
CAL-39NXzOOWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTJwMUS0PEAh|ryPMoXFV2FPT0WU
NCI-H2030NEfRXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LwVGlEPTB;Mj6xPFk4OyBizszNM1f6b3NCVkeHUh?=
HCT-116MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3ofIlpUUN3ME2yMlIzQTh2IDFOwG0>NFXDbYFUSU6JRWK=
HTC-C3M{fNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\OTWM2OD1{LkK2PFI1KCEQvF2=NYCyN|BlW0GQR1XS
TYK-nuMn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\1TWM2OD1{LkOwPVA6KCEQvF2=MkfLV2FPT0WU
FADUMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\4VmlEPTB;Mj6zNlI6PiBizszNM1X0fnNCVkeHUh?=
A431Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJwM{ewNlUhKM7:TR?=M4XnbHNCVkeHUh?=
TE-11NFvuXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDkbm5KSzVyPUKuN|gxOTliIN88US=>MULTRW5ITVJ?
CAL-12TNVO0O5djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7kVYNKSzVyPUKuOFA1OTdiIN88US=>MVjTRW5ITVJ?
DBMlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmS4TWM2OD1{LkSyPFY6KCEQvF2=NUHBbWpVW0GQR1XS
L-363NHr5R4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTJwNEO1NFchKM7:TR?=NXHxVXo4W0GQR1XS
MSTO-211HNXvESlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHMTWM2OD1{Lk[2N|kyKCEQvF2=NYW4VXBDW0GQR1XS
SK-UT-1NVf4RWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJwN{G0NFYhKM7:TR?=MY\TRW5ITVJ?
RPMI-8226MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTJwN{OxOlQhKM7:TR?=MkPlV2FPT0WU
SF295MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\uTWM2OD1{Lke0N|EhKM7:TR?=MVvTRW5ITVJ?
OS-RC-2NV7NflZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfsTWM2OD1{Lke2Olc{KCEQvF2=NVfudHhmW0GQR1XS
SK-MEL-24MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILPcZpKSzVyPUKuO|gzOjRiIN88US=>NWf3UYZEW0GQR1XS
COR-L23NWjuVFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknuTWM2OD1{Lke5OFY1KCEQvF2=NHnTZ5RUSU6JRWK=
MHH-PREB-1MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnuyTWM2OD1{LkiwNVYyKCEQvF2=NF;KephUSU6JRWK=
SK-N-DZNXXF[nhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTJwOEG2N|ghKM7:TR?=M1;Wc3NCVkeHUh?=
OMC-1NH[wcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnLOWNKSzVyPUKuPFUxODNiIN88US=>M1XaT3NCVkeHUh?=
SK-MEL-2NUDiO3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJwOEmyOFMhKM7:TR?=NWrsN4JlW0GQR1XS
SASMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTq[YVQUUN3ME2yMlk6PDF3IDFOwG0>M2LOVXNCVkeHUh?=
EPLC-272HMoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorPTWM2OD1|LkCwNlM2KCEQvF2=MWfTRW5ITVJ?
8505CNX3zUWx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTNwMUCzNFEhKM7:TR?=NFPkbWFUSU6JRWK=
EW-11NUHHZ2Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTNwMUSyO|chKM7:TR?=M4nsfnNCVkeHUh?=
YKG-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXadY1GUUN3ME2zMlE1PzB4IDFOwG0>NFHw[WlUSU6JRWK=
EC-GI-10MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LNbWlEPTB;Mz6xO|I3OyBizszNMmTjV2FPT0WU
SK-LU-1MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDadmxKSzVyPUOuNVg1OThiIN88US=>MlfVV2FPT0WU
P30-OHKMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfZe5hPUUN3ME2zMlIxOTF5IDFOwG0>NF6wfWJUSU6JRWK=
T-24MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYn4PGtwUUN3ME2zMlIyQDF2IDFOwG0>MnXlV2FPT0WU
HSC-2M3fzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTNwMkKyN|IhKM7:TR?=NUH2WVdTW0GQR1XS
SK-MES-1NWOyTlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\HeHBKSzVyPUOuNlQ5OjliIN88US=>MXXTRW5ITVJ?
SW48MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\kcphKSzVyPUOuNlU1QDZiIN88US=>MUXTRW5ITVJ?
ME-180MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHjd5hSUUN3ME2zMlI3ODVzIDFOwG0>NEHHSo5USU6JRWK=
NCI-H2009NIXTXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorNTWM2OD1|LkK5NFEhKM7:TR?=NXzBNYRJW0GQR1XS
HL-60M{DaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrBdWFCUUN3ME2zMlI6OTNiIN88US=>NXSwTmF3W0GQR1XS
NCI-N87NX;4[WNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3BWWFKSzVyPUOuN|AyPzJiIN88US=>NX\VelFzW0GQR1XS
GMS-10MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PRUWlEPTB;Mz6zOFA5PiBizszNNULFbmxJW0GQR1XS
SCHM4fJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTmTWM2OD1|LkSwPFQ1KCEQvF2=NFTYVmVUSU6JRWK=
C-33-AM4npPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrxTWM2OD1|LkSxOFIyKCEQvF2=MoHLV2FPT0WU
NCI-H1703NXHYWHk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTNwNEG4NVIhKM7:TR?=NWns[FhVW0GQR1XS
A427NXfCN4V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MluwTWM2OD1|LkS2NVI1KCEQvF2=M2\6bnNCVkeHUh?=
MOLT-4NISwbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;1TZhKSzVyPUOuOFgyQTliIN88US=>M3rrRXNCVkeHUh?=
NCI-H1792NGDTTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DtWmlEPTB;Mz60PVgxOiBizszNNXTsNW5RW0GQR1XS
NCI-H1650MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nQZ2lEPTB;Mz61O|I6KCEQvF2=MXvTRW5ITVJ?
H-EMC-SSNFXhUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DCcWlEPTB;Mz61PFU3QSBizszNNGLoNmNUSU6JRWK=
SW982M3\seWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7GTWM2OD1|LkW4PFI6KCEQvF2=NWnxe4JsW0GQR1XS
DSH1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfz[ZZOUUN3ME2zMlY1OTJ{IDFOwG0>NF;MXHBUSU6JRWK=
NOS-1MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnu[JVkUUN3ME2zMlY1Ojd4IDFOwG0>MnHuV2FPT0WU
BT-549NHi4[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTNwNke4OVQhKM7:TR?=NH60fWdUSU6JRWK=
HuCCT1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTNwN{SxO|chKM7:TR?=NF75S5pUSU6JRWK=
NCI-H1755MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTNwOU[5O|EhKM7:TR?=M1fGRXNCVkeHUh?=
KYSE-450M2\r[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTNwOU[5PVchKM7:TR?=NUn5W2RlW0GQR1XS
MIA-PaCa-2NVOwUo5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\vN4ZKSzVyPUOuPVczQSBizszNM1j5[3NCVkeHUh?=
U-266MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHjVoZKSzVyPUOuPVc1QDFiIN88US=>M3rNZXNCVkeHUh?=
MewoNE\jUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XNUmlEPTB;ND6wOlM3OSBizszNNEXU[5lUSU6JRWK=
KYSE-520NUHGRmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTRwMEm3PVkhKM7:TR?=MXTTRW5ITVJ?
MN-60MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\Pc3NKSzVyPUSuNVA2ODFiIN88US=>MoTHV2FPT0WU
Ramos-2G6-4C10M3HF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDJUlhpUUN3ME20MlE3PzN7IDFOwG0>MX\TRW5ITVJ?
SK-MEL-1M3z6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7LPYJKSzVyPUSuNVg3QTViIN88US=>NYLwcGJIW0GQR1XS
ABC-1MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF[4Oo9KSzVyPUSuNlM{OzNiIN88US=>M{X2d3NCVkeHUh?=
CAKI-1NVfvOWVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LReWlEPTB;ND6yOFU4OSBizszNM2\Ke3NCVkeHUh?=
HOSMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4q5RWlEPTB;ND6yPVE1OSBizszNNIDtTlhUSU6JRWK=
SN12CNInrdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2GwZ2lEPTB;ND6zOFI1PCBizszNMVvTRW5ITVJ?
NB13MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1uye2lEPTB;ND6zO|M2PSBizszNMVzTRW5ITVJ?
M14MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\1WVY{UUN3ME20MlQ5Pzl{IDFOwG0>MX7TRW5ITVJ?
GP5dNULhW4t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTRwNUCxNkAh|ryPMWDTRW5ITVJ?
NCI-H720MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFflfHZKSzVyPUSuOVM3OTJiIN88US=>MV7TRW5ITVJ?
D-423MGM3\aOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTRwNUO5NlQhKM7:TR?=MY\TRW5ITVJ?
ChaGo-K-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTRwNUm1OVkhKM7:TR?=MoHYV2FPT0WU
MEL-HOMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrIeWtEUUN3ME20MlYyOjZzIDFOwG0>MXPTRW5ITVJ?
MHH-ES-1NH\WNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmW1TWM2OD12Lk[yOFEyKCEQvF2=NVq1T2Z2W0GQR1XS
KYSE-270MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjObXFtUUN3ME20MlY2OTJ4IDFOwG0>NHjFeXJUSU6JRWK=
GI-ME-NMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\qe29KSzVyPUSuO|EzQTFiIN88US=>NHfkOZhUSU6JRWK=
HOP-92NVHrT3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1m5fGlEPTB;ND64NVM4QSBizszNMV7TRW5ITVJ?
MKN1MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTRwOEO5NVQhKM7:TR?=M1jxe3NCVkeHUh?=
ML-2NGfZcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTRwOEW2NlYhKM7:TR?=MWTTRW5ITVJ?
RO82-W-1MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnGTWM2OD12LkmyPVghKM7:TR?=NHzxVI1USU6JRWK=
G-361NFnSNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\RPYJKSzVyPUWuNFExODNiIN88US=>NH3C[GNUSU6JRWK=
HC-1NF3PUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTVwMEOyPVEhKM7:TR?=NWe2[GZMW0GQR1XS
EW-24MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLPSJlVUUN3ME21MlA1ODN6IDFOwG0>NXLQVpRvW0GQR1XS
HuP-T4NGLKempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnQ[4ppUUN3ME21MlE1OzN2IDFOwG0>MoThV2FPT0WU
8-MG-BANIq5VGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH6TWM2OD13LkO0NlghKM7:TR?=NIfSfHRUSU6JRWK=
HGC-27M1TBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPHTWM2OD13LkO3OlgzKCEQvF2=NIC1XlhUSU6JRWK=
TE-12NHLDWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrpTWM2OD13LkSxOVg2KCEQvF2=Mmr4V2FPT0WU
GT3TKBNVK5SoJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jOZWlEPTB;NT60OFIyOiBizszNMXnTRW5ITVJ?
DOHH-2NH;4VGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PEWmlEPTB;NT60OVk5PiBizszNNWq3VWl[W0GQR1XS
Ca-SkiMmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnH4TWM2OD13LkS2NVE2KCEQvF2=NVLSWJBbW0GQR1XS
A172NEflVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXYSY1KSzVyPUWuOVQ6OjViIN88US=>M{exXHNCVkeHUh?=
EGI-1NEDscVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG[4OIFKSzVyPUWuOVg6OzhiIN88US=>NHWzR2FUSU6JRWK=
MZ2-MELNYHofmFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkH0TWM2OD13Lk[xOFg3KCEQvF2=NEOwZVBUSU6JRWK=
SW1710M2Hmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3T5dWlEPTB;NT62PVA6OSBizszNNIPwUY9USU6JRWK=
HT-144NF3oTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:zTWM2OD13LkeyOlg2KCEQvF2=MUjTRW5ITVJ?
PA-1NYDzOFRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ezT2lEPTB;NT64NVg6OyBizszNNEnJZ4hUSU6JRWK=
HCC1937M3PiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nLcWlEPTB;NT64N|kzQSBizszNMWrTRW5ITVJ?
SK-OV-3MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn70TWM2OD13LkmxNVIyKCEQvF2=M1PGUHNCVkeHUh?=
K5MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHqN5l[UUN3ME22MlA2OTdiIN88US=>M4X0c3NCVkeHUh?=
NMC-G1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nnVmlEPTB;Nj6wO|c6PyBizszNNF;0VGxUSU6JRWK=
MDA-MB-361MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYO1fldXUUN3ME22MlA6OjZzIDFOwG0>NXLKS4JDW0GQR1XS
EKVXMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3lVZBKSzVyPU[uNVM2ODFiIN88US=>M1;z[XNCVkeHUh?=
ES7NV7vcJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzCTWM2OD14LkG2NVE2KCEQvF2=MmjMV2FPT0WU
KS-1MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4K0WmlEPTB;Nj6xO|k6OyBizszNNUnWUnVHW0GQR1XS
NCI-H661NXLvUXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTZwMUiwPFEhKM7:TR?=NY\vSFN7W0GQR1XS
ES8M2Pzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3S4NGlEPTB;Nj6xPFA5OiBizszNM2nnVXNCVkeHUh?=
NCI-H23M1H6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPUTWM2OD14LkKxPFE3KCEQvF2=MmjmV2FPT0WU
T47DNXTnfFZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;BcWlEPTB;Nj6yOlQ2PyBizszNNGHXR5BUSU6JRWK=
A2780MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjzPXhKSzVyPU[uN|c4ODFiIN88US=>M{X3WnNCVkeHUh?=
SCC-4MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTZwNEO1OlEhKM7:TR?=MVnTRW5ITVJ?
VA-ES-BJNGrSbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfNNVZrUUN3ME22Mlk4ODR|IDFOwG0>MWXTRW5ITVJ?
no-11Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrTVmtIUUN3ME23MlE3PDFiIN88US=>MnnhV2FPT0WU
KU-19-19NHWweJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\MeXVKSzVyPUeuNVY1PzZiIN88US=>Mn\JV2FPT0WU
MKN45MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjBTWM2OD15LkG4Olk6KCEQvF2=M2XnZ3NCVkeHUh?=
SCC-25NFj4XG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\ITWM2OD15LkKzOFE1KCEQvF2=MWnTRW5ITVJ?
ETK-1NVLOWVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTdwMkW1NVQhKM7:TR?=NH63N|hUSU6JRWK=
COR-L88NIDGeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3FTWM2OD15LkK5N|E6KCEQvF2=NH[wbJZUSU6JRWK=
8305CMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jKd2lEPTB;Nz6zNlQ6OiBizszNM4Tqe3NCVkeHUh?=
Detroit562M4\3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M325bWlEPTB;Nz6zNlUxPiBizszNMX\TRW5ITVJ?
SNU-449M1rVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\6fGlEPTB;Nz6zO|Y2OSBizszNMWnTRW5ITVJ?
A704MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\SZZNKSzVyPUeuN|gzPzhiIN88US=>NWrMb|Z7W0GQR1XS
D-502MGNIG0OpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjSRYlKSzVyPUeuN|g1PzNiIN88US=>MoG0V2FPT0WU
NCI-H2228NEjvR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;oWYpqUUN3ME23MlQyPDV6IDFOwG0>M4P4V3NCVkeHUh?=
CHP-212NYWwWFRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTdwNUG4PVYhKM7:TR?=M{naTHNCVkeHUh?=
VMRC-RCZNXjOTm52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3oTWM2OD15LkW5NFY3KCEQvF2=MkPrV2FPT0WU
RPMI-2650MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TvdGlEPTB;Nz63NFMyOiBizszNM2W3d3NCVkeHUh?=
HCC2218MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vqZmlEPTB;Nz63NlI2QCBizszNMUPTRW5ITVJ?
GCTMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofaTWM2OD15LkiyNVczKCEQvF2=NIO3fmJUSU6JRWK=
SW780NHe5dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlT4TWM2OD15Lkm5NFYhKM7:TR?=M3L5OnNCVkeHUh?=
KMOE-2NES2eGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7qTpBKSzVyPUiuNFQxPyBizszNMnHHV2FPT0WU
KYSE-180MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfneJhQUUN3ME24MlA5PjR6IDFOwG0>NYT3bGZ{W0GQR1XS
TE-1Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3j4S2lEPTB;OD6xNVA2PyBizszNNGr4WW5USU6JRWK=
OAW-42Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfFfFhKSzVyPUiuNlU1QTZiIN88US=>NITiUVFUSU6JRWK=
VM-CUB-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHn2R5NKSzVyPUiuNlg{PjRiIN88US=>M{O1ZnNCVkeHUh?=
ECC10MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DNcGlEPTB;OD6yPFM6PyBizszNMUjTRW5ITVJ?
SW1573M3qzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVT5W3VuUUN3ME24MlQ1PDZ3IDFOwG0>M3zOc3NCVkeHUh?=
NCI-H1299MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrrVmxKSzVyPUiuOVk4PzRiIN88US=>NEf6[|JUSU6JRWK=
ALL-POMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NViyOHA1UUN3ME24MlY3PTl5IDFOwG0>NGTa[YVUSU6JRWK=
OVCAR-5MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnkTWM2OD16Lke3OlI2KCEQvF2=M2PEfXNCVkeHUh?=
NCI-SNU-5NF35UXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTMTJJ5UUN3ME24Mlg{ODBzIDFOwG0>MUDTRW5ITVJ?
NCI-H2342NGHsNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHztTZFKSzVyPUiuPFMyODFiIN88US=>MYrTRW5ITVJ?
RPMI-7951NHX6UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2L1TGlEPTB;OD64OFE2PyBizszNNEX1ZWNUSU6JRWK=
RCM-1Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXSOlVKSzVyPUmuNFgyPDViIN88US=>NEizZXFUSU6JRWK=
DaoyNH7qNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\FW2lEPTB;OT6xNlAzQCBizszNMX;TRW5ITVJ?
HCC1395M3HBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjDTWM2OD17LkOwPFk3KCEQvF2=MnT5V2FPT0WU
786-0MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHQPWdkUUN3ME25MlM3ODJ4IDFOwG0>MYnTRW5ITVJ?
GAMGM4O5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjkbYNKSzVyPUmuOlU2OzRiIN88US=>MnrVV2FPT0WU
HCC1954Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LhfWlEPTB;OT64OVg2QSBizszNM17ucXNCVkeHUh?=
NCI-H1838NF[3OHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vDdWlEPTB;OT65NFM4OSBizszNMW\TRW5ITVJ?
SW620M3y5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGG0SlVKSzVyPUmuPVU{PTdiIN88US=>M4\qVnNCVkeHUh?=
NCI-H358NH7NNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTFyLkSxPVchKM7:TR?=M1e0d3NCVkeHUh?=
NCI-H1793NYHqUld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmW2TWM2OD1zMD60NlQ5KCEQvF2=NVTaXppqW0GQR1XS
NCI-H1666NXTUUZZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXCRmJKSzVyPUGwMlQ{PTViIN88US=>MWjTRW5ITVJ?
MZ7-melMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTpd5FwUUN3ME2xNE41PzV|IDFOwG0>NXH2UJJQW0GQR1XS
MDA-MB-175-VIIMnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLEUYVKSzVyPUGwMlY{QTZiIN88US=>NYjYT4ZjW0GQR1XS
COLO-829MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mor4TWM2OD1zMD64NFA1KCEQvF2=MWHTRW5ITVJ?
RVH-421NITEdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfJU5pEUUN3ME2xNU4yPTJiIN88US=>MnfxV2FPT0WU
A549MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEX3d3hKSzVyPUGxMlI1PzhiIN88US=>NFTq[YlUSU6JRWK=
DJM-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTFzLkO4N|MhKM7:TR?=MnnBV2FPT0WU
IST-MEL1MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M122TmlEPTB;MUGuO|MyQSBizszNNH;qW4RUSU6JRWK=
BENNUTDWoJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7UUXlKSzVyPUGxMlc1ODJiIN88US=>M{TzSHNCVkeHUh?=
KM12NWG0TJFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTJd3g1UUN3ME2xNU46ODlzIDFOwG0>NFrqXVlUSU6JRWK=
HuO9M{TjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\lcnFYUUN3ME2xNk4xPjZ4IDFOwG0>MUnTRW5ITVJ?
U-2-OSNEfmdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF{LkC4PVMhKM7:TR?=NVSz[4NSW0GQR1XS
RH-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGOyRphKSzVyPUGyMlQ1PzJiIN88US=>M2HzfHNCVkeHUh?=
NCI-H1048NXWwSolIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfKbmoxUUN3ME2xNk42PTB4IDFOwG0>MXLTRW5ITVJ?
Mo-TNWXpPFlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTUSFByUUN3ME2xNk44OzB5IDFOwG0>MlPWV2FPT0WU
KYSE-150MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYS5[WZ2UUN3ME2xNk44PDV3IDFOwG0>M17nU3NCVkeHUh?=
A388MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDMbFBKSzVyPUGyMlc4OTNiIN88US=>M4PpUXNCVkeHUh?=
NCI-SNU-1NEnkOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4ThdGlEPTB;MUKuPFA1PiBizszNM{HWXHNCVkeHUh?=
HELMoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3TTWM2OD1zMj64NlEzKCEQvF2=MmjnV2FPT0WU
UM-UC-3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{SycmlEPTB;MUKuPFg4PCBizszNM2rrb3NCVkeHUh?=
TGBC24TKBMliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPtTWM2OD1zMz6wNlY4KCEQvF2=NGe0XnVUSU6JRWK=
SW626MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjMU|FKSzVyPUGzMlI1QDViIN88US=>MoT6V2FPT0WU
ES6Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHn3dXZKSzVyPUGzMlI2OTJiIN88US=>M1XycnNCVkeHUh?=
NCI-H2029M{jEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTF|LkixNFghKM7:TR?=NH;hUnJUSU6JRWK=
RXF393MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHsXoFKSzVyPUGzMlk6OjdiIN88US=>NFzXc2lUSU6JRWK=
HMV-IINGHBOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTF2LkC3PEAh|ryPM1i0N3NCVkeHUh?=
EW-22NUDHfYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[3N4RuUUN3ME2xOE4yPTB{IDFOwG0>NYqy[WRFW0GQR1XS
AsPC-1M37h[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrsTWM2OD1zND61OlQhKM7:TR?=MXTTRW5ITVJ?
COLO-678NWm4em8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;rWmJMUUN3ME2xOE44OjdzIDFOwG0>M3HBUnNCVkeHUh?=
HCT-15NULRUnpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHezPHNKSzVyPUG0Mlg5PTViIN88US=>MXvTRW5ITVJ?
HCE-TMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjWT|ZKSzVyPUG0Mlg5PzRiIN88US=>NWHnVVlqW0GQR1XS
SF539NVPCUY9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzuNYJPUUN3ME2xOU4xPjR|IDFOwG0>MorDV2FPT0WU
AU565NYSxfJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPiTWM2OD1zNT6yNFk3KCEQvF2=Mke3V2FPT0WU
JVM-2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFm1TZVKSzVyPUG1MlI3QDFiIN88US=>MkWwV2FPT0WU
CaR-1NUL5fo9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYO4TIxNUUN3ME2xOU41PDF{IDFOwG0>Ml:xV2FPT0WU
23132-87NVHuUHRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDyTWM2OD1zNT64OFk2KCEQvF2=MoLkV2FPT0WU
A673Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELY[3lKSzVyPUG1Mlk3OzZiIN88US=>NFW1PJNUSU6JRWK=
KYSE-410MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTF4LkCyPUAh|ryPM1vxfXNCVkeHUh?=
TE-9MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFftUnJKSzVyPUG2MlA3OiBizszNNHTIOXVUSU6JRWK=
LU-139MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HsWGlEPTB;MU[uNVgzOyBizszNMWrTRW5ITVJ?
GCIYMmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7tfmhYUUN3ME2xOk4yQTF4IDFOwG0>NX;5bpB3W0GQR1XS
JEG-3MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfubFVKSzVyPUG2MlI2KCEQvF2=NHu3SmZUSU6JRWK=
RT-112M4\uUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfLTWM2OD1zNj60NVQ{KCEQvF2=MXXTRW5ITVJ?
COLO-680NM4O0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTF4LkWxNFghKM7:TR?=NXvYVVZWW0GQR1XS
LU-134-AM376SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fBXGlEPTB;MU[uPVg6OyBizszNM1facHNCVkeHUh?=
MFM-223NUDzepBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LC[2lEPTB;MUeuNVU{PSBizszNMUnTRW5ITVJ?
SF126M3Pkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TUR2lEPTB;MUeuNVcxOSBizszNMoLVV2FPT0WU
NCI-H28NWjO[nY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPzW4VKSzVyPUG3MlIxPjZiIN88US=>MWrTRW5ITVJ?
BFTC-905M{jxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF5LkS4N|IhKM7:TR?=NGPvfm1USU6JRWK=
SCC-9NX[zWJo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDhTWM2OD1zNz62Nlg2KCEQvF2=M{D0c3NCVkeHUh?=
KNS-62MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDqe3FKSzVyPUG3MlY3OjliIN88US=>Mn7MV2FPT0WU
Hs-578-TNHq5TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTF5LkixOFkhKM7:TR?=MnjlV2FPT0WU
D-336MGNXfCRZZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnO5TWM2OD1zNz64Nlk1KCEQvF2=M3LzbXNCVkeHUh?=
NCI-H82NHXvOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{[wZ2lEPTB;MUiuNFE5OyBizszNM4jvVXNCVkeHUh?=
EFM-19NYnafZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoC4TWM2OD1zOD6wOVc4KCEQvF2=MX\TRW5ITVJ?
TGBC11TKBMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTF6LkGwNlEhKM7:TR?=MkD5V2FPT0WU
HEC-1M2LmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTF6LkK5NVghKM7:TR?=MWXTRW5ITVJ?
HuP-T3NEX2TGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\zW4pVUUN3ME2xPE42QTJ7IDFOwG0>NHjYd3hUSU6JRWK=
SF268Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvFOHZKSzVyPUG4MlY4ODJiIN88US=>NFf5UW5USU6JRWK=
COLO-792MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2r6N2lEPTB;MUiuO|k6PyBizszNNGfPbYdUSU6JRWK=
HLEMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTF6LkizN|EhKM7:TR?=MlrNV2FPT0WU
A204NWDCW45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkD6TWM2OD1zOD65NVY1KCEQvF2=MkDTV2FPT0WU
CAL-72MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWe4bVNXUUN3ME2xPU4xQDd5IDFOwG0>MUfTRW5ITVJ?
U031NIm1b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrFbWRKSzVyPUG5MlQ6ODliIN88US=>MkTZV2FPT0WU
FTC-133MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TmXGlEPTB;MUmuPVMxPCBizszNNWfueIZnW0GQR1XS
SK-MEL-28NImzTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXvdm5KSzVyPUKwMlM4PjFiIN88US=>MoPoV2FPT0WU
KGNMoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFW2PYVKSzVyPUKwMlQ3QTliIN88US=>MoPQV2FPT0WU
HCC2998Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HF[GlEPTB;MkGuN|kzPiBizszNNIXjOVZUSU6JRWK=
GOTONYPOOIpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjpXIF3UUN3ME2yNU41QDViIN88US=>M133UHNCVkeHUh?=
AGSNH\h[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTJzLki0OVEhKM7:TR?=NV2yWVg2W0GQR1XS
EW-13NFvXNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJ{LkGwNlIhKM7:TR?=MnS3V2FPT0WU
P12-ICHIKAWAMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfv[2gxUUN3ME2yNk4yPjB|IDFOwG0>NEjnS5NUSU6JRWK=
NCI-H1395M2f4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTJ{LkK5NFchKM7:TR?=NYXRZnlYW0GQR1XS
A2058NVm2clZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX76OYR6UUN3ME2yNk41OzRiIN88US=>M32xbnNCVkeHUh?=
SH-4MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PxOGlEPTB;MkKuO|A1PSBizszNM4[4eXNCVkeHUh?=
DoTc2-4510NUj5dnN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PVTmlEPTB;MkOuOlQ4OiBizszNNG\HNo9USU6JRWK=
MMAC-SFNWLJOXdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{CxVGlEPTB;MkOuOlkyOSBizszNNX3WcXVtW0GQR1XS
NCI-H510ANWSzcJRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTJ|Lke5N|khKM7:TR?=NUXNZ2ZrW0GQR1XS
HDLM-2M2n3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjUT5dKSzVyPUK0MlE1PiBizszNNITqNZVUSU6JRWK=
KINGS-1NW\0UHdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTJ2LkK0NkAh|ryPNIDIRWNUSU6JRWK=
NCI-H1648MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLXTWM2OD1{ND60NFI1KCEQvF2=M17Ib3NCVkeHUh?=
HCC1187MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn:4TWM2OD1{NT6wNlM2KCEQvF2=NW\jT5N5W0GQR1XS
BALL-1NVzOTnNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTJ3LkKwOlIhKM7:TR?=NFuwWmtUSU6JRWK=
SBC-1Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\mfJNNUUN3ME2yOU4zQTl|IDFOwG0>MmnxV2FPT0WU
BFTC-909NFHsUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTJ3LkO1OVEhKM7:TR?=M33UNHNCVkeHUh?=
MOLT-13MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIroU2NKSzVyPUK1MlY4PDRiIN88US=>MXfTRW5ITVJ?
SW1990MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\sT|AxUUN3ME2yOU46PjV3IDFOwG0>M3vtW3NCVkeHUh?=
DK-MGNYPLXpZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJ4LkC0OFMhKM7:TR?=M3vjO3NCVkeHUh?=
TE-8M1PFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PIemlEPTB;Mk[uNFY3QCBizszNNWjxc244W0GQR1XS
BeckerNUOx[YptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjpTWM2OD1{Nj6xOVc1KCEQvF2=MonxV2FPT0WU
KYSE-70M1jwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2f6NGlEPTB;Mk[uOVMyPyBizszNNULicGRsW0GQR1XS
MKN7MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\lTWlEPTB;MkeuO|Q4QSBizszNNFH2N3VUSU6JRWK=
D-392MGNGL5PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTJ5Lke2PVQhKM7:TR?=MlLRV2FPT0WU
NH-12M{X6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjzfo1KSzVyPUK4MlEzOjliIN88US=>NUG5XFEyW0GQR1XS
EW-18NFP5e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTMcXBKSzVyPUK4MlIzOThiIN88US=>NUXw[VByW0GQR1XS
LCLC-97TM1NGrTUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETlRpBKSzVyPUK4MlI4PjJiIN88US=>M4jUUHNCVkeHUh?=
NCI-H1770NWDU[WNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJ6LkO1OlYhKM7:TR?=NFfWUnlUSU6JRWK=
BT-20NWrP[HJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYWzd4FXUUN3ME2yPE4{Pjh3IDFOwG0>NGPPXmZUSU6JRWK=
DBTRG-05MGNWXac455T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTJ6LkS4N|ghKM7:TR?=NUGwcWFsW0GQR1XS
HPAF-IIM{\n[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfzbWRKSzVyPUK4Mlc4QSBizszNNV7rUpVTW0GQR1XS
SW837NX\KfIJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XwO2lEPTB;MkmuN|M5PSBizszNMXnTRW5ITVJ?
647-VNHO0SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTJ7LkewNFMhKM7:TR?=NVTLXm9iW0GQR1XS
J82M3LQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTJ7LkiwNVMhKM7:TR?=MYLTRW5ITVJ?
MC116Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFi4ZWJKSzVyPUOwMlA4OzNiIN88US=>MX7TRW5ITVJ?
NCI-H69NFjJcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvWTWM2OD1|MD62NFk{KCEQvF2=M1rXV3NCVkeHUh?=
NB6NFmxXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13kfmlEPTB;M{GuN|YzQSBizszNNVfMTWZ5W0GQR1XS
CAL-120NWXjTG9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTN{LkSzNVchKM7:TR?=MVHTRW5ITVJ?
U-87-MGNHXwc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfXeWxKSzVyPUOzMlAzPTFiIN88US=>MonoV2FPT0WU
NCI-H1304MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDYWmtKSzVyPUOzMlA{PTRiIN88US=>NX;vco5qW0GQR1XS
YH-13NV7TN4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;XT5BRUUN3ME2zN{4zPTN3IDFOwG0>MVLTRW5ITVJ?
RMG-INYDUR2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTN|LkSyPFUhKM7:TR?=M4TyeHNCVkeHUh?=
LU-65NVHmNY5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTN2LkG0NFghKM7:TR?=MYrTRW5ITVJ?
GB-1NFLtPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHy1c2lKSzVyPUO1MlA4OjliIN88US=>NXfBZ|lnW0GQR1XS
DU-4475MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInSc5BKSzVyPUO1MlE2PTNiIN88US=>MXLTRW5ITVJ?
SBC-5NX\PUoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnpXm9KSzVyPUO2MlU6ODJiIN88US=>NFzNTZRUSU6JRWK=
OE33NVHKcmd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1r0PGlEPTB;M{euO|U4PyBizszNM{Pud3NCVkeHUh?=
C8166M4T1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S1UWlEPTB;M{iuOVI3PyBizszNMUTTRW5ITVJ?
COLO-684NYrURpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XuSGlEPTB;M{iuO|QzQCBizszNNXG2U4Q3W0GQR1XS
NCI-H1155MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTN7LkC0O|EhKM7:TR?=M1KwcHNCVkeHUh?=
ATN-1NVHmRYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTN7Lke3PVIhKM7:TR?=M3zMUnNCVkeHUh?=
KARPAS-299NH;ENYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fTO2lEPTB;M{muPFM6KCEQvF2=MYrTRW5ITVJ?
KNS-81-FDM3zibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlL0TWM2OD12MD6zOlA1KCEQvF2=NUDSWHlWW0GQR1XS
NCI-H1563M4TiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zQSGlEPTB;NEGuOVA{QSBizszNNEPt[JJUSU6JRWK=
NB14MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTR{LkeyOlMhKM7:TR?=M4[0WnNCVkeHUh?=
COLO-800MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml64TWM2OD12Mj64OVE4KCEQvF2=NU\MUWhCW0GQR1XS
MS-1NELiS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\xeYFoUUN3ME20N{4xPDh|IDFOwG0>MV3TRW5ITVJ?
OVCAR-8MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmToTWM2OD12Mz62PFA6KCEQvF2=NUTwb4hoW0GQR1XS
SK-PN-DWM4rNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TKNWlEPTB;NEOuPFc4PiBizszNNF:1cXFUSU6JRWK=
G-402NU\0e5FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfIZ2FKSzVyPUSzMlkxODZiIN88US=>MV;TRW5ITVJ?
NCI-H2291MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXDSIZKSzVyPUS0MlgxOTdiIN88US=>M3nWOHNCVkeHUh?=
PC-3NXjTXpJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPNd3hJUUN3ME20OU45ODJ|IDFOwG0>MYjTRW5ITVJ?
NCI-H1581M3;GUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPHTWM2OD12NT65PFg6KCEQvF2=MUjTRW5ITVJ?
SW1116MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnz3TWM2OD12Nz6wNVgzKCEQvF2=MY\TRW5ITVJ?
ZR-75-30M{D1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTR5LkCyN|khKM7:TR?=NILacIxUSU6JRWK=
OCI-AML2M1LwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnyW2l2UUN3ME20O{4xQTF6IDFOwG0>NVLGU4VVW0GQR1XS
MDA-MB-231MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVW5WYdPUUN3ME20O{43OjR7IDFOwG0>MUPTRW5ITVJ?
ES3MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTmTWM2OD12OD6zOVI6KCEQvF2=M2L2VXNCVkeHUh?=
NCI-H630MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjSeXpKSzVyPUS5MlE4PDJiIN88US=>MkfGV2FPT0WU
OE19MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljnTWM2OD12OT6yPVAzKCEQvF2=MUnTRW5ITVJ?
NCI-H1573MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zUc2lEPTB;NEmuOlg3OSBizszNNVztc2V1W0GQR1XS
EW-1M1vYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTR7LkmwPFQhKM7:TR?=MkfHV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02810990 Not yet recruiting Chronic Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto September 2016 Phase 2
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Customer Product Validation(3)


Click to enlarge
Rating
Source J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck
Method Endothelial cell permeability assay
Cell Lines Human endothelial cells
Concentrations 0-10 μM
Incubation Time 15-60 min
Results Figure C defines concentrations of kinase inhibitors which block ANDV-induced EC permeability approximately 50% (IC50s). IC50s of bosutinib are 100 nM and 10 μM. we next assessed the abilities of bosutinib to block ANDV-induced permeability at its IC50s from 15 to 60 min after VEGF addition, we find that bosutinib inhibited ANDV-induced permeability up to 40 to 50% but only at IC50s of 10 μM(Figure D).

Click to enlarge
Rating
Source J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines Mouse sperm
Concentrations 0-50 μM
Incubation Time 60 min
Results In the case of SKI606, a sharp inhibitory effect was observed at 50 μM.

Click to enlarge
Rating
Source Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines sperm
Concentrations 50 μΜ
Incubation Time
Results PKA and tyrosine phosphorylation was rescue by Ser/Thr phosphatase inhibitors SKI-606 and SU6656.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us